dalteparin has been researched along with Cytokine Release Syndrome in 3 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, A | 1 |
| Ali, M | 1 |
| Griffin, DO | 1 |
| Jensen, A | 1 |
| Khan, M | 1 |
| Chin, J | 1 |
| Chin, K | 1 |
| Saad, J | 1 |
| Parnell, R | 1 |
| Awwad, C | 1 |
| Patel, D | 1 |
| Sukhdeo, S | 1 |
| Negroponte, E | 1 |
| Rajasekhar, H | 1 |
| Gaur, S | 1 |
| Horton, DB | 1 |
| Malhotra, A | 1 |
| Moorthy, LN | 1 |
3 other studies available for dalteparin and Cytokine Release Syndrome
| Article | Year |
|---|---|
Case Report: Home-based Management of Severe COVID-19 with Low-dose Tofacitinib.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; COVID-19 Drug Treatment; Cytokine Rele | 2021 |
Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease.
Topics: Acute Disease; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Betacoronavirus; Biomarkers; | 2020 |
Acute respiratory distress syndrome and COVID-19 in a child with systemic lupus erythematosus.
Topics: Antiviral Agents; Child, Preschool; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Cy | 2021 |